Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

British Journal of Cancer

Volumn 106, Issue 4, 2012, Pages 673-677

  Brain, E ^a   Isambert, N ^b,c   Dalenc, F ^d   Dieras V ^a   Bonneterre, J ^e   Rezai, K ^a   Jimenez, M ^f   Mefti Lacheraf, F ^a   Cottura, E ^d   Tresca, P ^a   Vanlemmens, L ^e   Mahier Ait Oukhatar C ^f   Lokiec, F ^a   Fumoleau, P ^b  

^a INSTITUT CURIE   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c INSERM   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f FNCLCC   (France)

Author keywords

anti HER2 therapy; breast cancer; lapatinib; phase I study; vinorelbine

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG POTENTIATION; FEASIBILITY STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MYALGIA; NEUTROPENIA; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEASIBILITY STUDIES; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2; VINBLASTINE;

EID: 84856940693     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.591     Document Type: Article

References (26)

1. Bai F, Freeman III BB, Fraga CH, Fouladi M, Stewart CF (2006) Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/ MS). J Chromatogr B Analyt Technol Biomed Life Sci 831: 169-175 (Pubitemid 43155792)
2. Blackwell K, Kaplan EH, Franco SX, Marcom PK, Maleski J, Sorensen M, Berger MS (2004) A phase II open-label, multcenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing regimens. Ann Oncol 15 (suppl 3): 27 (Abstract 103O)
3. BursteinHJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP (2001) Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722-2730 (Pubitemid 32441378)
4. Burstein HJ, Storniolo AM, Franco S, Forster J, Stein S, Rubin S, Salazar VM, Blackwell KL (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19: 1068-1074 (Pubitemid 351796331)
5. Chan A (2007) A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann Oncol 18: 1152-1158 (Pubitemid 47244359)
6. Chan A, Martin M, Untch M, Gil MG, Guillem-Porta V, Wojtukiewicz M, Kellokumpu-Lehtinen P, Sommer HL, Georgoulias V, Battelli N, Pawlicki M, Aubert D, Bourlard T, Gasmi J, Villanova G, Petruzelka L (2006) Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: An international phase II trial. Br J Cancer 95: 788-793 (Pubitemid 44498091)
7. Chew HY, X Somlo G, Gitlitz B, Christensen S, Linden H, Davies A (2009) A phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Eur J Cancer Suppl 7: 129
8. Dean-Colomb W, Esteva FJ (2008) Her2-positive breast cancer: Herceptin and beyond. Eur J Cancer 44: 2806-2812
9. Delozier T, Guastalla JP, Yovine A, Levy C, Chollet P, Mousseau M, Delva R, Coeffic D, Vannetzel JM, Zazzi ES, Brienza S, Cvitkovic E (2006) A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Anticancer Drugs 17: 1067-1073 (Pubitemid 44454784)
10. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743 (Pubitemid 46021510)
11. Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S (2011) The efficacy of HER2-targeted agents in metastatic breast cancer: A meta-analysis. Ann Oncol 12: 1308-1317
12. Kajita J, Kuwabara T, Kobayashi H, Kobayashi S (2000) CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 28: 1121-1127 (Pubitemid 30660369)
13. Lu Y-SL, Shen Y-C, Lan CY, Huang S-M, Cheng A-L, Huang C-S (2010) Result of a phase I part of a phase I/II study of lapatinib plus oral vinorelbine in metastatic breast cancer patients overexpressing ErbB2. In San Antonio Breast Cancer Symposium, P3-14-18, San Antonio, TX
14. MartyM, Fumoleau P, Adenis A, Rousseau Y,MerroucheY, RobinetG, Senac I, Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12: 1643-1649 (Pubitemid 34070598)
15. Moy B, Goss PE (2006) Lapatinib: Current status and future directions in breast cancer. Oncologist 11: 1047-1057 (Pubitemid 44788395)
16. Nahta R, Esteva FJ (2006) HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8: 215
17. Nahta R, Yuan LX, Du Y, Esteva FJ (2007) Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol Cancer Ther 6: 667-674 (Pubitemid 46332467)
18. Rezai K, Urien S, Isambert N, Roche H, Dieras V, Berille J, Bonneterre J, Brain E, Lokiec F (2011) Pharmacokinetic evaluation of the vinorelbinelapatinib combination in the treatment of breast cancer patients. Cancer Chemother Pharmacol 68: 1529-1536
19. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K (2001) The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer. Cancer Res 61: 7196-7203 (Pubitemid 32946515)
20. Sano M, Tokuda Y, Noguchi S, Aogi K, Saeki T, Tabei T, Hatake K, Fujii H (2006) A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer. Gan To Kagaku Ryoho 33: 1091-1097
21. Savio G, Laudani A, Leonardi V, Pepe A, Scianna C, Gebbia V, Agostara B (2006) Treatment of metastatic breast cancer with vinorelbine and docetaxel. Am J Clin Oncol 29: 276-280 (Pubitemid 44270936)
22. Scheffler M, Di Gion P, Doroshyenko O, Wolf J, Fuhr U (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: Focus on 4-anilinoquinazolines. Clin Pharmacokinet 50: 371-403
23. Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK, Chan EC (2010) Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol 78: 693-703
24. Van Heugen JC, De Graeve J, Zorza G, Puozzo C (2001) New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces. J Chromatogr A 926: 11-20 (Pubitemid 32739002)
25. Xia W, Liu LH, Ho P, Spector NL (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23: 646-653 (Pubitemid 38241266)
26. Zhou XJ, Rahmani R (1992) Preclinical and clinical pharmacology of vinca alkaloids. Drugs 44(Suppl 4): 1-16; discussion 66-9 (Pubitemid 23025990)